Cart
sales@molnova.com
Linvencorvir
CAS No. 1808248-05-6
Linvencorvir( —— )
Catalog No. M35768 CAS No. 1808248-05-6
Linvencorvir is a hepatitis B virus (HBV) core protein variant modifier used to treat chronic HBV infection.
Purity : >98% (HPLC)
COA
Datasheet
HNMR
HPLC
MSDS
Handing Instructions
| Size | Price / USD | Stock | Quantity |
| 1 mL x 10 mM in DMSO | 330 | In Stock |
|
| 5MG | 250 | In Stock |
|
| 10MG | 359 | In Stock |
|
| 25MG | 581 | In Stock |
|
| 50MG | 761 | In Stock |
|
| 100MG | 1014 | In Stock |
|
| 200MG | 1376 | In Stock |
|
| 500MG | Get Quote | In Stock |
|
| 1G | Get Quote | In Stock |
|
Biological Information
-
Product NameLinvencorvir
-
NoteResearch use only, not for human use.
-
Brief DescriptionLinvencorvir is a hepatitis B virus (HBV) core protein variant modifier used to treat chronic HBV infection.
-
DescriptionLinvencorvir is an antiviral agent.
-
In Vitro——
-
In Vivo——
-
Synonyms——
-
PathwayMicrobiology/Virology
-
TargetHBV
-
RecptorHBV | Antibiotic
-
Research Area——
-
Indication——
Chemical Information
-
CAS Number1808248-05-6
-
Formula Weight598.69
-
Molecular FormulaC29H35FN6O5S
-
Purity>98% (HPLC)
-
SolubilityIn Vitro:?DMSO : 62.5 mg/mL (104.39 mM; Ultrasonic (<60°C)
-
SMILESC(OCC)(=O)C=1[C@@H](NC(=NC1CN2C[C@@]3(N(CC2)C(=O)N(CC(C(O)=O)(C)C)C3)[H])C4=NC=CS4)C5=C(C)C(F)=CC=C5
-
Chemical Name——
Shipping & Storage Information
-
Storage(-20℃)
-
ShippingWith Ice Pack
-
Stability≥ 2 years
Reference
1. International Nonproprietary Names for Pharmaceutical Substances (INN). WHO Drug Information, Vol. 35, No. 4, 2021
molnova catalog
related products
-
Helioxanthin derivat...
Helioxanthin derivative 5-4-2 （Helioxanthin 5-4-2） is an analogue of helioxanthin that shows anti-HBV activity in vitro and can be used to study HBV.
-
Canocapavir
Canocapavir (ZM-H1505R) is a novel orally available HBV coat protein modulator with antiviral activity that induces conformational changes in the linker region of the HBV core protein, and can be used for the treatment of hepatitis B virus.
-
BCM-599
BCM-599 is an efficient HBV capsid assembly inhibitor with in vitro IC50 of 13 uM, shows synergistic inhibitory effects on decreasing viral concentration combined with lamivudine in vivo.
